212 related articles for article (PubMed ID: 26800997)
21. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
22. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
23. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Digestion; 2008; 77(3-4):225-35. PubMed ID: 18667823
[TBL] [Abstract][Full Text] [Related]
25. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
[TBL] [Abstract][Full Text] [Related]
26. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
28. Modern Management of Irritable Bowel Syndrome: More Than Motility.
Tack J; Vanuytsel T; Corsetti M
Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
[TBL] [Abstract][Full Text] [Related]
29. Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study.
Sohn W; Lee OY; Kwon JG; Park KS; Lim YJ; Kim TH; Jung SW; Kim JI
Neurogastroenterol Motil; 2012 Sep; 24(9):860-e398. PubMed ID: 22679908
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
32. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study.
Hawrelak JA; Myers SP
J Altern Complement Med; 2010 Oct; 16(10):1065-71. PubMed ID: 20954962
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
Hirata T; Funatsu T; Keto Y; Nakata M; Sasamata M
Inflammopharmacology; 2007 Feb; 15(1):5-9. PubMed ID: 17323187
[TBL] [Abstract][Full Text] [Related]
34. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
Zheng Y; Yu T; Tang Y; Xiong W; Shen X; Jiang L; Lin L
PLoS One; 2017; 12(3):e0172846. PubMed ID: 28291778
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.
Lembo AJ; Cremonini F; Meyers N; Hickling R
Aliment Pharmacol Ther; 2010 May; 31(9):979-90. PubMed ID: 20163375
[TBL] [Abstract][Full Text] [Related]
37. Treatment of irritable bowel syndrome with a novel colonic irrigation system: a pilot study.
Hsu HH; Leung WH; Hu GC
Tech Coloproctol; 2016 Aug; 20(8):551-7. PubMed ID: 27194235
[TBL] [Abstract][Full Text] [Related]
38. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
[TBL] [Abstract][Full Text] [Related]
39. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
Lembo A; Rao SSC; Heimanson Z; Pimentel M
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
